Evidence map›Paper›PMID 42181581›Full record

ArticleBrain, behavior, & immunity - health2026

Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.

Fatima Afaar, Priscilla Youssef, Laura Hughes, Michelle Chua, Elie Matar, Woojin S Kim, Glenda M Halliday, Simon J G Lewis, Nicolas Dzamko

Abstract read
In one paragraph

Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fatima AfaarSchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, NSW, 2050, Australia.
Priscilla YoussefSchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, NSW, 2050, Australia.
Laura HughesSchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, NSW, 2050, Australia.
Michelle ChuaSchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, NSW, 2050, Australia.
Elie MatarSydney Medical School, Faculty of Medicine and Health, Brain and Mind Centre, University of Sydney, Department of Neurology, Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia.
Woojin S KimSchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, NSW, 2050, Australia.
Glenda M HallidaySchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, NSW, 2050, Australia.
Simon J G LewisParkinson's Disease Research Clinic, Macquarie Medical School, Macquarie University, 75 Talavera Road, NSW, Australia.
Nicolas DzamkoSchool of Medical Sciences, Faculty of Medicine and Health and the Brain and Mind Centre, University of Sydney, Camperdown, NSW, 2050, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Emerging evidence indicates that peripheral immune changes occur in patients with isolated REM sleep behaviour disorder (iRBD) and may contribute to the conversion of this dream enactment disorder to a neurodegenerative synucleinopathy such as Parkinson's disease, dementia with Lewy bodies or multiple system atrophy. However, with only a limited number of studies conducted, the extent to which immune changes occur across diverse iRBD cohorts remains to be determined. Objectives: We therefore aimed to assess peripheral immune changes in an Australian cohort of iRBD patients (n = 65) compared to controls (n = 35). Methods: A 9-plex cytokine assay was used to measure serum levels of IFNγ, IL-10, IL-12, IL-17A, IL-1β, IL-2, IL-4, IL-6 and TFNα. Flow cytometry was used to assess T cell populations in the same participants. Results: Exploratory analyses revealed lower levels of the T cell regulating cytokine interleukin 2 (IL-2) in participants with iRBD, along with lower frequencies of CD4 T cells positive for IL-2, IL-4 and IL-10. Conclusions: These results add to evidence of immune alterations in iRBD and suggest that dysregulation of cytokines with anti-inflammatory properties may be an early event that could associate with subsequent development of a neurodegenerative synucleinopathy.

Identifiers

PMID42181581
PMCPMC13195789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.